Biogen and Neomorph announced research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and immunological diseases. Neomorph receives upfront plus potential milestones totaling up to $1.45B, research cost reimbursement, and mid-single to low-double digit royalties. Biogen advances clinical candidates.